All Thromboembolic Events- Tamoxifen Trials

Trial NameNLength of Treatment (years)Length of FU (years)PlaceboTamoxifenRR95% CINotes
PlaceboTamoxifenNo.RateNo.Rate
Royal Marsden
Powles, 200726123312387.813.230.3180.822.620.69–9.87Active treatment
Powles, 20072612331238813.265Post treatment P = 1.0
Powles, 199825123312385.80.850.680.850.26–2.79
Italian
Dicensi, 2005272708270051190.94101.021.090.44–2.68on treatment
IBIS
Cuzick, 2007203375357958362.02683.8Active treatment
Cuzick, 20072035753579242.24262.42Post treatment
NSABP
Fisher, 19982467076681442.81.07532.031.91.20–3.00

From: Appendix D, Evidence Tables

Cover of Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women
Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women [Internet].
AHRQ Comparative Effectiveness Reviews, No. 17.
Nelson HD, Fu R, Humphrey L, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.